Why the study?
Many clinical trials with rAAV vectors have reported varying degrees of immunotoxicity, including serious adverse events, highlighting the need to address immunogenic features in vector design.
Reducing immunogenic features such as CpG motifs in rAAV vectors may help avoid immunotoxicity and accelerate successful clinical product development.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
J. Fraser Wright (2020) conducted an editorial in Genetic diseases. Recombinant adeno-associated virus (rAAV) vectors was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: